The XJO is expected to rally on open this morning following a rebound overnight in the U.S. Their futures are flat this morning. Recently we have been leading the U.S. Yesterday we rebounded from key support at roughly 7,700, and roughly where the uptrend line comes in. The U.S overnight followed suit. GDP data came
Read More
Medical device company Atomo Diagnostics (ASX: AT1) has locked in purchase orders from Viatris Healthcare Pty Ltd amounting to approximately $970,000 for HIV Self-Tests. These tests, manufactured by Atomo under the Mylan brand, are designated for supply to several Low- and Middle-Income Countries (LMICs). The orders are scheduled for production during the second half of
Read More
Despite global efforts, food waste remains a challenging problem to solve. Each year, 1.3 billion tons of food is wasted due to poor handling, costing the global economy $1.5 trillion. This waste contributes 6-8% of annual greenhouse gas emissions and, what’s more, if saved, it could have fed about 1.26 billion people. No doubt, food
Read More
The XJO is expected to open flat this morning despite a strong pullback in the U.S overnight. Yesterday we pulled back to form an evening star reversal pattern. We also led the U.S, who followed us lower overnight, however their move was far more exaggerated. Our mute response to their pullback overnight, aside from us
Read More
Aussie clinical stage biotech company Cynata Therapeutics (ASX: CYP) has marked a milestone in its Phase 2 clinical trial of CYP-001 for high-risk acute graft versus host disease (aGvHD) with the enrolment and treatment of its first patient. High-risk acute graft versus host disease (aGvHD) is a serious complication that can occur after a stem
Read More
While the artificial intelligence industry has been a big winner from the bumper financials delivered by semiconductor company NVIDIA last month, shareholders of semiconductor equipment firm Revasum (ASX: RVS) are still waiting to see the share price gains delivered by peers. The wait could take another two weeks, with Revasum extending its voluntary suspension in
Read More
